An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
DRUG

Canakinumab

Canakinumab

Trial Locations (73)

1011

Novartis Investigative Site, Lausanne

1020

Novartis Investigative Site, Laken

1094

Novartis Investigative Site, Budapest

1200

Novartis Investigative Site, Brussels

3000

Novartis Investigative Site, Leuven

9000

Novartis Investigative Site, Ghent

13125

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

16147

Novartis Investigative Site, Genova

20100

Novartis Investigative Site, Milan

20122

Novartis Investigative Site, Milan

20246

Novartis Investigative Site, Hamburg

22081

Novartis Investigative Site, Hamburg

24576

Novartis Investigative Site, Bad Bramstedt

28009

Novartis Investigative Site, Madrid

28034

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

31096

Novartis Investigative Site, Haifa

34098

Novartis Investigative Site, Fatih / Istanbul

34722

Novartis Investigative Site, Istanbul

35340

Novartis Investigative Site, Balcova / Izmir

35392

Novartis Investigative Site, Giessen

40202

Novartis Investigative Site, Louisville

43205

Novartis Investigative Site, Columbus

45229

Novartis Investigative Site, Cincinnati

46026

Novartis Investigative Site, Valencia

48149

Novartis Investigative Site, Münster

49202

Novartis Investigative Site, Petah Tikva

50132

Novartis Investigative Site, Florence

53757

Novartis Investigative Site, Saint Augustin

67098

Novartis Investigative Site, Strasbourg

69120

Novartis Investigative Site, Heidelberg

69677

Novartis Investigative Site, Lyon

72076

Novartis Investigative Site, Tübingen

75015

Novartis Investigative Site, Paris

76100

Novartis Investigative Site, Rehovot

79106

Novartis Investigative Site, Freiburg im Breisgau

80131

Novartis Investigative Site, Napoli

82467

Novartis Investigative Site, Garmisch-Partenkirchen

90027

Novartis Investigative Site, Los Angeles

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

97232

Novartis Investigative Site, Portland

115522

Novartis Investigative Site, Moscow

119991

Novartis Investigative Site, Moscow

194100

Novartis Investigative Site, Saint Petersburg

4428164

Novartis Investigative Site, Kfar Saba

5266202

Novartis Investigative Site, Ramat Gan

02111

Novartis Investigative Site, Boston

C1270AAN

Novartis Investigative Site, CABA

A-1090

Novartis Investigative Site, Vienna

80060-900

Novartis Investigative Site, Curitiba

20551-030

Novartis Investigative Site, Rio de Janeiro

21941-912

Novartis Investigative Site, Rio de Janeiro

04023-900

Novartis Investigative Site, São Paulo

Unknown

Novartis Investigative Site, Vancouver

M5G 1X8

Novartis Investigative Site, Toronto

H3T 1C5

Novartis Investigative Site, Montreal

115 27

Novartis Investigative Site, Ampelokipoi

Novartis Investigative Site, Goudi- Athens

546 39

Novartis Investigative Site, Thessaloniki

3584 EA

Novartis Investigative Site, Utrecht

05

Novartis Investigative Site, Breña

02-637

Novartis Investigative Site, Warsaw

08950

Novartis Investigative Site, Esplugues de Llobregat

171 76

Novartis Investigative Site, Stockholm

06100

Novartis Investigative Site, Ankara

BS2 8BJ

Novartis Investigative Site, Bath

B4 6NH

Novartis Investigative Site, Birmingham

L12 2AP

Novartis Investigative Site, Liverpool

WC1N 1EH

Novartis Investigative Site, London

M9 2AA

Novartis Investigative Site, Manchester

NE4 4LP

Novartis Investigative Site, Newcastle Upon Tyme

OX3 7LD

Novartis Investigative Site, Oxford

Sponsors
All Listed Sponsors
collaborator

Pediatric Rheumatology International Trials Organization

OTHER

lead

Novartis Pharmaceuticals

INDUSTRY